Antianginal'naya terapiya: fokus na ranolazin


Cite item

Full Text

Abstract

Антиангинальные препараты (препараты, предупреждающие приступы стенокардии) за счет профилактики ишемии миокарда значительно улучшают самочувствие больных и повышают переносимость ими физической нагрузки. В настоящее время рекомендованы для применения 7 групп антиангинальных препаратов: b-адреноблокаторы (БАБ), антагонисты кальция (АК), нитраты, ингибиторы If-каналов клеток синусового узла, метаболические препараты, никорандил и новый препарат ранолазин.

About the authors

Yu. A Karpov

Институт клинической кардиологии им.А.Л.Мясникова ФГБУ РКНПК Минздрава РФ

References

  1. ВНОК. Диагностика и лечение стабильной стенокардии. Российские рекомендации (второй пересмотр). Кардиоваскулярная терапия и профилактика (Прил. 4). 2008.
  2. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Guidelines on the management of stable angina pectoris: executive summary. Eur Heart J 2006; 27: 1341–81.
  3. Карпов Ю.А., Сорокин Е.В. Стабильная ИБС: стратегия и тактика лечения. 3-е изд. М.: МИА, 2012.
  4. ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients with Stable Ischemic Heart Disease. Circulation 2012; 126: e354–e471.
  5. Aslam S, Gray D. Ranolazine (Ranexa) in the treatment of chronic stable angina. Adv Ther 2010; 27 (4): 193–201.
  6. Letienne R, Vie B, Puech A et al. Evidence that ranolazine behaves as a weak beta1and beta2 - adrenoceptor antagonist in the cat cardiovascular system. Naunyn Schmiedebergs. Arch Pharmacol 2001; 363 (4): 464–71.
  7. Allely M.C, Brown C.M, Kenny B.A et al. Modulation of alpha 1 - adrenoceptors in rat left ventricle by ischaemia and acyl carnitines: Protection by ranolazine. J Cardiovasc Pharmacol 1993; 21 (6): 869–73.
  8. Zhao G, Walsh E, Shryock J.C et al. Antiadrenergic and hemodynamic effects of ranolazine in conscious dogs. J Cardiovasc Pharmacol 2011; 57 (6): 639–47.
  9. Chaitman B.R, Skettino S.L, Parker J.O et al. Anti - ischemic effects and long - term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004; 43 (8): 1375–82.
  10. Estacion M, Waxman S.G, Dib-Hajj S.D. Effects of ranolazine on wild - type and mutant hNav1.7 channels and on DRG neuron excitability. Mol Pain 2010; 6: 35.
  11. Melloni C, Newby L.K. Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study. Expert Rev Cardiovasc Ther 2008; 6 (1): 9–16.
  12. Dobesh P.P, Trujillo T.C. Ranolazine: A new option in the management of chronic stable angina. Pharmacotherapy 2007; 27 (12): 1659–76.
  13. Siddiqui M.A, Keam S.J. Ranolazine: A review of its use in chronic stable angina pectoris. Drugs 2006; 66 (5): 693–710.
  14. Chaitman B.R, Pepine C.J, Parker J.O et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: A randomized controlled trial. JAMA 2004; 291 (3): 309–16.
  15. US Food and Drug Administration. Available from: http://www.fda. gov/ohrms/dockets/ac/03/briefing/4012B2_01_Action%20Letter.pdf. Accessed April 4, 2007.
  16. Stone P.H, Gratsiansky N.A, Blokhin A et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006; 48 (3): 566–75.
  17. Morrow D.A, Scirica B.M, Karwatowska-Prokopczuk E et al. Evaluation of a novel anti - ischemic agent in acute coronary syndromes: Design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non - ST - elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. Am Heart J 2006; 151 (6): e1181–e1189.
  18. Arnold S.V, Morrow D.A, Lei Y et al. Economic impact of angina after an acute coronary syndrome: Insights from the MERLIN-TIMI 36 trial. Circ Cardiovasc Qual Outcomes 2009; 2 (4): 344–53.
  19. Arnold S.V, Morrow D.A, Wang K et al. Effects of ranolazine on disease - specific health status and quality of life among patients with acute coronary syndromes: Results from the MERLIN - TIMI 36 randomized trial. Circ Cardiovasc Qual Outcomes 2008; 1 (2): 107–15.

Copyright (c) 2013 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies